You just read:

Spitfire Pharma's SP-1373 outscored semaglutide and elafibranor in a biopsy-proven translational mouse model of non-alcoholic steatohepatitis (NASH)

News provided by

Spitfire Pharma, Inc.

Jan 04, 2018, 11:19 ET